HIV/AIDS Therapy

U.S. FDA grants approval for new Kaletra tablet formulation for HIV patients

Published in Medical Letter on the CDC and FDA, December 18th, 2005

Abbott Laboratories announced that it has received U.S. Food and Drug Administration (FDA) approval for a new tablet formulation of its HIV protease inhibitor (PI) Kaletra (lopinavir/ritonavir), which will allow adult patients to take fewer pills with or without food as part of their treatment regimen.

Additionally, there will be no refrigeration requirements for the tablets. These benefits were not available with the old Kaletra capsules. The standard daily doses of new Kaletra tablets and capsules provide similar drug levels in the blood.

Kaletra is the number one prescribed PI for the treatment of HIV worldwide and has been taken by hundreds of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry